Related Experiment Videos

Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells

Rohini Gomathinayagam1, Srinivasan Sowmyalakshmi, Firdaus Mardhatillah

  • 1Department of Clinical Sciences, College of Health Sciences, University of Kentucky, Lexington, KY 40536-0200, USA.

Anticancer Research
|May 30, 2008
PubMed
Abstract

Insights

Plumbagin, a natural compound, shows anticancer effects against non-small cell lung cancer (NSCLC) by inducing apoptosis. It effectively inhibits NSCLC cell growth and modulates key signaling pathways involved in cell survival and death.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Lung cancer is a leading cause of cancer mortality.
  • Current treatments for non-small cell lung cancer (NSCLC) have limited efficacy due to therapy resistance.
  • Novel therapeutic strategies are urgently needed for lung cancer treatment.

Purpose of the Study:

  • To investigate the anticancer effects of plumbagin on NSCLC cell lines.
  • To elucidate the molecular mechanisms underlying plumbagin's anti-cancer activity in NSCLC.

Main Methods:

  • Cell viability assays were performed on H460 and A549 NSCLC cell lines.
  • Western blot and reporter assays were utilized to analyze signaling pathways.
  • Apoptosis assays were conducted to assess programmed cell death induction.

Main Results:

  • Plumbagin significantly inhibited H460 cell growth more than A549 cells.
  • Plumbagin down-regulated EGFR/Neu signaling and pro-survival proteins (Akt, NF-kappaB, Bcl-2, survivin) in H460 cells.
  • Plumbagin induced G2/M cell cycle arrest via p53/p21 upregulation and activated JNK/p38 signaling, leading to apoptosis.

Conclusions:

  • Plumbagin demonstrates significant anticancer activity against NSCLC cells.
  • Plumbagin modulates pro-survival and pro-apoptotic signaling pathways to induce cancer cell death.
  • Plumbagin represents a potential therapeutic agent for NSCLC treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...